Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5363 plus paclitaxel in triple-negative advanced or metastatic breast cancer
2013-001521-43Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing AZD5363 + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001521-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001521-43.